PHAGIX™ FORTE P — broadest poultry coverage.
E. coli · Salmonella · C. perfringens — tri-pathogen phage cocktail with select probiotics. The primary commercial finished good for farms, distributors, and veterinary practices.
Product specifications.
The E. coli + Salmonella phage backbone is validated in vivo across three peer-reviewed poultry trials (broilers n=1,500 · layers n=2,400 · Ma-chicken n=1,050; Ge L. et al., Feed Research 2020–2022). The C. perfringens phage component is platform-supported — in vitro lytic activity has been confirmed and a Clostridium poultry trial summary is on file, but this component has not yet been validated as a finished SKU. A confirmatory field trial is planned.
Three pathogens. One formulation.
FORTE P targets the three dominant causes of enteric disease and performance loss in commercial poultry. Each phage component is host-specific — non-target microbiota are unaffected.
Colibacillosis & enteric infection
- Colibacillosis — systemic E. coli infection
- Pericarditis and perihepatitis
- Salpingitis and peritonitis in layers
- Bacterial diarrhea, increased mortality
- Reduced growth, elevated FCR
Salmonellosis & food safety
- Cecal colonization and systemic infection
- Reduced feed intake and growth rate
- Zoonotic risk — eggs and meat
- Reduced hatchability in breeders
- Regulatory compliance pressure
Necrotic enteritis (NE)
- Acute NE — rapid mortality spikes
- Subclinical NE — silent FCR degradation
- Intestinal lesions, wet litter
- Increased susceptibility to coccidiosis
- Estimated cost: >US$6 billion/year globally
The lytic cycle.
Five-step lytic mechanism
Phage binds to specific receptor proteins on the target bacterium. Non-target organisms are not recognized.
Phage DNA enters the bacterial cell.
Host cell machinery produces 50–200 new phage particles per cycle.
Bacterial cell wall ruptures, releasing progeny phages that propagate through remaining pathogens.
Once pathogen density falls below threshold, replication ceases. No residues. No accumulation.
Three peer-reviewed trials across the E. coli + Salmonella backbone.
Performance Summary — Three Trials
| Endpoint | Broilers (42 d) | Layers (30 d) | Ma-Chicken (35 d) |
|---|---|---|---|
| FCR improvement | −7.4% | −5.0% | −4.6% |
| Growth/production | ADG +5.3% | Lay rate +2.5% | ADG +5.4% |
| Mortality reduction | −55% | Not reported | −46% |
| Diarrhea/defect rate | −70% diarrhea | −57% def. eggs | Not reported |
| E. coli log reduction | −1.39 log | −1.36 log | AMP combination |
| Salmonella log reduction | −1.49 log | −1.22 log | AMP combination |
| IgG immune response | Not tested | Not tested | +49% |
| Source: Ge L. et al., Feed Research 2020 (04) 111–115; 2020 (07); 2022 (07). Authorized translations on file. Dose: 200 g/MT (broilers), 300 g/MT (layers), 100 g/MT + AMP (Ma-chicken). | |||
Request the FORTE P datasheet.
Product overview, certificate of analysis, inclusion rate guidance, authorized translations of the three peer-reviewed trials, and the PHAGIX Introduction Book. Our team will recommend a dosing program for your species and challenge profile.